Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caulerpin is a bis-indole alkaloid predominantly isolated from marine algae of the genus *Caulerpa*, particularly *Caulerpa racemosa* and *Caulerpa cylindracea*. This naturally occurring compound is characterized by its vibrant red color and unique chemical structure featuring two indolic rings connected by an eight-membered ring with carbonyl groups[3][4][10]. Caulerpin exhibits diverse biological activities including **antiviral** properties (particularly against HSV-1 and Chikungunya virus), **anti-inflammatory**, **anticancer**, **antinociceptive**, **spasmolytic**, **antifungal**, **acetylcholinesterase inhibitor**, **antibacterial**, and **antituberculosis** activities[3][4][7]. The compound demonstrates potent antiviral activity with an EC50 of 0.8 μM against Chikungunya virus and shows approximately 90% viral inhibition at 5 μM concentration[5]. For HSV-1, caulerpin inhibits the alpha and beta phases of the viral replication cycle and has been proposed as an alternative to acyclovir[7]. The molecular formula is C24H18N2O4 with a molecular weight of 398.41[6][8]. Recent studies have also investigated its delivery via cubosomes nanocarriers for enhanced pharmaceutical applications[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caulerpin.